Crystallized oxalate decarboxylase and methods of use
Oxalate decarboxylase crystals, including stabilized crystals, such as cross-linked crystals of oxalate decarboxylase, are disclosed. Methods to treat a disorder associated with elevated oxalate concentration using oxalate decarboxylase crystals are also disclosed. Additionally disclosed are methods of producing protein crystals.
1. A method of reducing oxalate in a mammal, the method comprising orally administering a composition comprising uncrosslinked oxalate decarboxylase crystals to the mammal in an amount sufficient to reduce the oxalate, wherein said crystals are active and stable in the gastrointestinal tract of the mammal.
2. The method of claim 1 , wherein said crystals are active and stable at about pH 2 to about pH 8.
3. The method of claim 1 , wherein administration of the composition results in a reduction of oxalate of at least 10%.
4. A method of treating a disorder associated with elevated oxalate concentration in a mammal, the method comprising orally administering uncrosslinked oxalate decarboxylase crystals to the mammal in an amount sufficient to reduce one or more symptoms associated with the disorder, wherein said crystals are active and stable in the gastrointestinal tract of the mammal.
5. The method of claim 4 , wherein the disorder is related to a kidney or a liver function.
6. The method of claim 4 , wherein the disorder is selected from the group consisting of primary hyperoxaluria, enteric hyperoxaluria, idiopathic hyperoxaluria, ethylene glycol poisoning, cystic fibrosis, inflammatory bowel disease, urolithiasis, nephrolithiasis, chronic kidney disease, hemodialysis, and gastrointestinal bypass.
7. The method of claim 1 , wherein administration of the composition results in a reduction of oxalate of at least 20%.
8. The method of claim 1 , wherein administration of the composition results in a reduction of oxalate of at least 30%.
9. The method of claim 1 , wherein administration of the composition results in a reduction of oxalate of at least 40%.
10. The method of claim 1 , wherein administration of the composition results in a reduction of oxalate of at least 50%.
11. The method of claim 4 , wherein administration of the composition results in a reduction of oxalate of at least 10%.
12. The method of claim 4 , wherein administration of the composition results in a reduction of oxalate of at least 20%.
13. The method of claim 4 , wherein administration of the composition results in a reduction of oxalate of at least 30%.
14. The method of claim 4 , wherein administration of the composition results in a reduction of oxalate of at least 40%.
15. The method of claim 4 , wherein administration of the composition results in a reduction of oxalate of at least 50%.